Is Fennec Pharmaceuticals Inc. (NASDAQ:FENC) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Fennec Pharmaceuticals Inc. at current levels.
A single-drug company solving childhood deafness from chemo, with a label expansion that could 3x the addressable market.
Where FENC is headed
Fennec is the strangest kind of biotech success story. One drug, PEDMARK, that prevents pediatric cancer survivors from going deaf after cisplatin chemotherapy. No pipeline to speak of. Roughly 1,500 kids a year in the US who need it. And yet here we are in mid-2026 with 72% revenue growth, 92% gross margins, and a forward earnings number that implies this thing actually works as a business.
Read the full Compass Direction on FENC
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $8.77).
See the full FENC analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Fennec Pharmaceuticals Inc. (NASDAQ:FENC) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Fennec Pharmaceuticals Inc. at current levels. A single-drug company solving childhood deafness from chemo, with a label expansion that could 3x the addressable market.
What is FENC's Compass Score?
Fennec Pharmaceuticals Inc. scores 81/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for FENC?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the FENC page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.